Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

NCT03219970 · clinicaltrials.gov ↗

COMPLETED

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Osimertinib

Sponsor

AstraZeneca